---
title: Effect of Strength and Conditioning Training on Functional Performance in Children With Chronic Kidney Disease
nct_id: NCT05657236
overall_status: UNKNOWN
phase: NA
sponsor: Cairo University
study_type: INTERVENTIONAL
primary_condition: Chronic Kidney Diseases
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05657236.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05657236"
ct_last_update_post_date: 2022-12-20
last_seen_at: "2026-05-12T07:20:50.913Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Strength and Conditioning Training on Functional Performance in Children With Chronic Kidney Disease

**NCT ID:** [NCT05657236](https://clinicaltrials.gov/study/NCT05657236)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Cairo University
- **Conditions:** Chronic Kidney Diseases
- **Start Date:** 2023-02-01
- **Completion Date:** 2024-02-15
- **CT.gov Last Update:** 2022-12-20

## Brief Summary

Despite the benefits of physical rehabilitation among adults and children with chronic illness, they avoid to engage in different physical activities especially pediatric population. Most of the children with Chronic kidney disease receive their medical treatment and follow-up with no change of their functional performance. We still lack the evidence of plyometric exercises in pediatric population with Chronic kidney disease . Therefore, the primary aim of this study is to explore the effects of strength and conditioning training in the form of plyometric exercises on balance and muscle strength in children with Chronic kidney disease .

## Eligibility

- **Minimum age:** 6 Years
- **Maximum age:** 6 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age will be ranged from 6-10 years.
* Both genders were included.
* Can follow instructions.
* Medically stable sedentary children with CKD, GFR (stage 2 (mild) eGFR of 60-89 ml/min per 1.73 m2, stage 3 (moderate) eGFR 30-59 ml/min per 1.73 m2) stage 4 (severe) eGFR of 15-29 ml/min per 1.73 m2.
* Did not yet require renal replacement therapy (non-dialysis).

Exclusion Criteria:

* Recent myocardial infarction, uncontrolled hypertension, unstable angina, symptomatic left ventricular fibrillation.
* Severe uncontrolled diabetes,
* Neurological or cognitive disorders
* Peripheral vascular disease.
```

## Arms

- **control group** (OTHER)
- **Experimental group** (EXPERIMENTAL)

## Interventions

- **medical treatment** (OTHER) — traditional medical treatment and regular follow-up
- **plyometric exercise** (OTHER) — Each session starts with a 5-minute warm-up of flexibility exercises (active range motion and stretching exercises).The main plyometric exercise set will be applied for 20-30 minutes and consisted of 10 exercises directed at the lower body that gradually progress by increasing the set/repetition number in two exercise blocks, each continue for 1 month .The cool down period is 5 minutes and includes walking at self-preferred speed and static stretches of the major muscle groups.

## Primary Outcomes

- **Balance** _(time frame: after 2 months)_ — The Human Assessment Computer (HUMAC), a computerized dynamic posturography (commuter sports medicine, Inc., Stoughton, MA),will be used in the current study.
- **muscle strength** _(time frame: after 2 months)_ — The Laffayette manual muscle testing (model 01163 USA) is used for objectively quantifying muscle strength including hip flexors and abductors; knee flexors and extensors

## Locations (1)

- Amira Mahmoud Abd-elmonem, Giza, Egypt

## Recent Field Changes (last 30 days)

- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.amira mahmoud abd-elmonem|giza||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05657236.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05657236*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*